The earnings results for ImmunoPrecise Antibodies IPA for Q2 were made public on Tuesday, December 10, 2024 at 08:30 AM.
Here's a comprehensive overview of the announcement.
Earnings
ImmunoPrecise Antibodies missed estimated earnings by -40.0%, reporting an EPS of $-0.07 versus an estimate of $-0.05.
Revenue was down $136 thousand from the same period last year.
Analysis of Past Earnings
Last quarter the company missed on EPS by $0.03 which was followed by a 7.000000000000001% increase in the share price the next day.
Here's a look at ImmunoPrecise Antibodies's past performance:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.08 | -0.08 | -0.07 | -0.100 |
| EPS Actual | -0.11 | -0.58 | -0.08 | -0.074 |
| Revenue Estimate | 4.96M | 4.72M | 4.50M | 4.33M |
| Revenue Actual | 3.87M | 4.72M | 4.55M | 4.62M |
To track all earnings releases for ImmunoPrecise Antibodies visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
